Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The aim of study is to investigate whether hematological inflammatory biomarkers could be useful to detect patients with lung cancer.
Methods: The contribution of hematological biomarkers to the diagnosis of lung cancer and prediction of TNM was examined.
Results: NLR, PLR, MPV values were found to be higher in patients with lung cancer (all < .001). NLR and PLR were found to be high, MPV was found to be lower in disease of advanced stage ( < .001).
Conclusions: This study found that NLR, PLR and MPV values were significantly higher in patients with lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07357907.2021.1938110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.
JCO Precis Oncol
September 2025
Shu-Ning Li, MS, Jun-Nv Xu, MD, PhD,and Nan-Nan Ji, MD, PhD, Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, China, Ming Xue, MS, Department of Outpatient, The Second Affiliated Hospital of Hainan Medical University, Hai
Identification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFReply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.
JCO Precis Oncol
September 2025
Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart
The staging evolution dilemma: TNM-9 sharpens anatomical precision, but is biology still offstage?
J Bras Pneumol
September 2025
. Rede D'Or, São Paulo (SP), Brasil.
Out with the old - advancements and shortcomings of the updated 9th edition of the Tumor, Node, Metastasis (TNM) classification system for lung cancer.
J Bras Pneumol
September 2025
. Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal.
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).
View Article and Find Full Text PDF